RxDoctor Payments Data

Rolando Acevedo, MD

Internal Medicine · Pembroke Pines, FLNPI 1245284090

Payments from drug & device makers

$247in general payments, 2019–2025

Across 9 payments — averaging $27.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argon Medical Devices, Inc.$101
  • AstraZeneca$33
  • Boehringer Ingelheim$29
  • Exact Sciences$26
  • Lilly USA, LLC$25
  • Novo Nordisk$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$23194%
  • Gifts$166%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Argon Medical Devices, Inc.1$101
AstraZeneca2$33
Boehringer Ingelheim2$29
Exact Sciences1$26
Lilly USA, LLC1$25
Novo Nordisk1$16
Ascend Therapeutics US, LLC1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$247 in reported general payments places this provider in the 40th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$60,828
Medicare patients
149
Services billed
825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol76$66,521
EliquisApixaban54$64,524
JardianceEmpagliflozin39$40,637
TradjentaLinagliptin42$36,745
JanuviaSitagliptin Phosphate32$30,823
XareltoRivaroxaban27$26,658
OzempicSemaglutide14$16,003
TrulicityDulaglutide11$15,978
JanumetSitagliptin Phos/Metformin Hcl16$15,725
LinzessLinaclotide19$14,809
EntrestoSacubitril/Valsartan15$14,610
Xigduo XrDapaglifloz Propaned/Metformin11$6,303
Atorvastatin Calcium508$4,265
Rosuvastatin Calcium317$4,118
Levothyroxine Sodium295$3,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$29$77,38281 claims
AstraZenecaFarxiga, Symbicort$33$69,91590 claims
Novo NordiskOzempic$16$16,00314 claims
Lilly USA, LLCTrulicity$25$15,97811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Pembroke Pines

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →